Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

Read more breaking news


EFSA health claim opinion

EFSA turns down beta-glucan immunity health claim

By Lorraine Heller , 28-May-2010
Last updated on 28-May-2010 at 13:34 GMT2010-05-28T13:34:38Z

The latest negative health claim opinion from the European Food Safety Authority (EFSA) finds no immune benefits linked to a yeast extract supplied by German firm Leiber.

EFSA’s Panel on Dietetic Products, Nutrition and Allergies found that the 17 scientific references submitted by Leiber for its branded Yestimun ingredient did not demonstrate how the ingredient could help reduce the common cold.

Submitted under article 13.5, the claimed effect was for “reducing the risk for common cold infections by decreasing the susceptibility for common cold infections during the cold season by strengthening the body’s natural defences and improving the body’s immune defence against common cold viral infections during the cold season”.

Studies dismissed

Leiber had submitted 10 human studies, five animal studies and two in vitro studies in support of Yestimun, a beta-glucan ingredient derived from brewer’s yeast cell wall.

However, EFSA dismissed four of the human studies as they had been conducted using intravenously injected beta-glucans, which was considered to be an “inappropriate route of exposure”.

An additional four human studies that used oral administration were also dismissed as the changes of immune parameters did not represent “an improvement on the initiation of appropriate innate and adaptive immune responses.”

Another study was dismissed because it recruited a very small number of subjects, there was a high drop out rate, a multiplicity of ‘primary outcomes’, and a lack of adjustment for multiple testing. Another study was not found to have statistically significant results.

EFSA’s NDA panel also said that that the “evidence provided in animal and in vitro studies does not predict an effect of Yestimun on the initiation of appropriate innate and adaptive immune responses in humans.”

The panel concluded that a cause and effect relationship was not established between the consumption of Yestimun and the initiation of appropriate innate and adaptive immune responses.

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Balancing Innovation and Risk in Sports Nutrition Ingredients
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars